Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology

Video

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

In an interview with CancerNetwork®,Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed encouraging research in the field of urologic oncology.

Transcription:

From a new treatment standpoint, some of [the most interesting] areas in prostate, kidney, and bladder cancer [are] the continued immunotherapy developments. Another one that’s very relevant to our world today is continued disparities research. [With] disparities, everyone always initially tends to think of gender and racial disparities; I think inherent into that [are] also very significant socioeconomic and also geographic disparities.

I think there’s going to be new ways of providing urologic care and telemedicine will be one tool for that. I do not think that…telemedicine will fix all disparity access issues for urologic care. I think that that is an over promise for this technology. But I think it can help and it can be used as a tool [for] the person who lives 500 miles away from a referral center [who has] a unique cancer that probably should…at least have treatment guided by that referral center. [This technology] makes it just a lot easier for them to get the input because they don’t have to drive 500 miles or fly that far. They can just have a telemedicine visit from their couch and say, ‘Okay, my local provider can do this, this is great. Thank you so much for your guidance and input,’ and [get] on with their day.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content